Skip to main content

Advertisement

SpringerLink
Log in

Evaluation of Cytotoxic Activity of New Benzimidazole-Piperazine Hybrids Against Human MCF-7 and A549 Cancer Cells

  • Published:
Pharmaceutical Chemistry Journal Aims and scope

A series of benzimidazole-piperazine hybrids (14 – 37) were designed, synthesized and evaluated for their cytotoxic activity against human lung (A549) and breast (MCF-7) cancer cell lines. Preliminary evaluation revealed that most of these hybrid molecules (i.e., 16 – 25) exhibited noteworthy and preferential antiproliferative effect against human lung cancer (A549) with IC50 values of 2.8 – 7.8 μM. Among the synthesized molecules, compound 17 showed the most balanced cytotoxic effect against lung (A549) and breast (MCF-7) cancer cells with IC50 values of 5.4 and 4.2 μM, respectively. To explore the mechanistic aspects fundamental to the observed activity, further biological studies of compounds 16, 17 and 22 were carried out. In addition, these compounds induced PARP-1 cleavage and caspase 7 activation, caused morphological changes such as bleb formation in the treated cells, and significantly increased the nuclear fragmentation. Taken all together, our findings indicate that cytotoxic activities of newly synthesized benzimidazole-piperazine hybrids are mediated through the apoptotic cell death induction. These benzimidazole derivatives have the potential for further development as anticancer agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Scheme 1.
Fig. 1.
Fig. 2.
Fig. 3.
Fig. 4.

Similar content being viewed by others

References

  1. Global Cancer Facts & Figures, 3rd Edition, Atlanta: American Cancer Society (2015).

  2. R. S. Keri, A. Hiremathad, S. Budagumpi, et al., Chem. Biol. Drug Des., 86, 19 – 65 (2015).

    Article  Google Scholar 

  3. P. Singla, V. Luxami, and K. Paul, Rsc. Adv., 4, 12422 – 12440 (2014).

    Article  CAS  Google Scholar 

  4. G. Yadav and S. Ganguly, Eur. J. Med. Chem., 97, 419 – 443 (2015).

    Article  CAS  Google Scholar 

  5. B. Caliskan, A. Yilmaz, I. Evren, et al., Med. Chem. Res., 22, 782 – 793 (2013).

    Article  CAS  Google Scholar 

  6. B. D. Cheson and L. Leoni, Clin. Adv. Hematol. Oncol., 9, 1 – 11 (2011).

    PubMed  Google Scholar 

  7. M. Gentile, A. G. Recchia, C. Mazzone, et al., Expert. Opin. Pharmacother., 14, 2263 – 2280 (2013).

    Article  CAS  Google Scholar 

  8. F. C. Torres, M. E. Garcia-Rubino, C. Lozano-Lopez, et al., Curr. Med. Chem., 22, 1312 – 1323 (2015).

    Article  CAS  Google Scholar 

  9. W. Wang, D. Kong, H. Cheng, et al., Bioorg. Med. Chem. Lett., 24, 4250 – 4253 (2014).

    Article  CAS  Google Scholar 

  10. A. S. Alpan, S. Zencir, I. Zupko, et al., J. Enzym. Inhib. Med. Chem., 24, 844 – 849 (2009).

    Article  CAS  Google Scholar 

  11. N. Shrivastava, M. J. Naim, M. J. Alam, et al., Arch Pharm., 350(6) (2017).

  12. Y. K. Yoon, M. A. Ali, A. C. Wei, et al., Eur. J. Med. Chem., 83, 448 – 454 (2014).

    Article  CAS  Google Scholar 

  13. Y. K. Yoon and T. S. Choon, Arch. Pharm., 349, 1 – 8 (2016).

    Article  CAS  Google Scholar 

  14. M. K. Akkoc, M. Y. Yuksel, I. Durmaz, et al., Turk. J. Chem., 36, 515 – 525 (2012).

    Google Scholar 

  15. A. M. Saab, M. Dobmeier, B. Koenig, et al., Anticancer Res., 33, 3027 – 3032 (2013).

    CAS  PubMed  Google Scholar 

  16. M. Tuncbilek, E. B. Guven, T. Onder, et al., J. Med. Chem., 55, 3058 – 3065 (2012).

    Article  CAS  Google Scholar 

  17. A. M. Waszkielewicz, A. Gunia, N. Szkaradek, et al., Bioorg. Med. Chem. Lett., 23, 4419 – 4423 (2013).

    Article  CAS  Google Scholar 

  18. E. H. Cho, S. G. Chung, S. H. Lee, et al., WO1998000402 A1 (1998).

  19. J. H. Lee, D. W. Kang, H. S. Kwon, et al., Arch. Pharm. Res., 27, 436 – 441 (2004).

    Article  CAS  Google Scholar 

  20. M. Tuncbilek, E. B. Guven, T. Onder, et al., Med. Chem., 55, 3058 – 3065 (2012).

    Article  CAS  Google Scholar 

  21. E. Banoglu, B. Caliskan, S. Luderer, et al., Bioorg. Med. Chem., 20, 3728 – 3741 (2012).

    Article  CAS  Google Scholar 

  22. E. Banoglu, E. Celikoglu, S. Volker, et al., Eur. J. Med. Chem., 113, 1 – 10 (2016).

    Article  CAS  Google Scholar 

  23. S. N. Baytas, N. Inceler, A. Yilmaz, et al., Bioorg. Med. Chem., 22, 3096 – 3104 (2014).

    Article  CAS  Google Scholar 

  24. S. Cankara Pirol, B. Caliskan, I. Durmaz, et al., Eur. J. Med. Chem., 87, 140 – 149 (2014).

    Article  CAS  Google Scholar 

  25. A. Ozdemir,M. Yildiz, F. S. Senol, et al., Food. Chem. Toxicol., 109, 898 – 909 (2017).

    Article  CAS  Google Scholar 

  26. P. K. Dubey, P. V. V. P. Reddy, and K. Srinivas, Synth. Commun., 37, 1675 – 1681 (2007).

    Article  CAS  Google Scholar 

  27. R. U. Jänicke, Breast Cancer Res. Treat., 117(1), 219 – 21 (2009).

    Article  Google Scholar 

  28. D. Boucher, V. Blais, and J. B. Denault, Proc. Natl. Acad. Sci. USA, 109(15), 5669 – 74 (2012).

    Article  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by the Scientific and Technological Research Council of Turkey (TUBITAK Grant No: 115S016).

Author information

Authors and Affiliations

  1. Department of Pharmacology, Faculty of Pharmacy, Gazi University, 06330, Ankara, Turkey

    Aysun Özdemir & Mustafa Arka

  2. Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Gazi University, 06330, Ankara, Turkey

    Sümeyye Turanli, Burcu Çalişkan & Erden Banoglu

Authors
  1. Aysun Özdemir
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sümeyye Turanli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Burcu Çalişkan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mustafa Arka
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Erden Banoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aysun Özdemir.

Ethics declarations

Conflict of Interest

The authors state no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Özdemir, A., Turanli, S., Çalişkan, B. et al. Evaluation of Cytotoxic Activity of New Benzimidazole-Piperazine Hybrids Against Human MCF-7 and A549 Cancer Cells. Pharm Chem J 53, 1036–1046 (2020). https://doi.org/10.1007/s11094-020-02119-9

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11094-020-02119-9

Keywords

Search

Navigation